608 related articles for article (PubMed ID: 15250751)
1. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Friedman M; Menjoge SS; Anton SF; Kesten S
Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
[TBL] [Abstract][Full Text] [Related]
3. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
4. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
[TBL] [Abstract][Full Text] [Related]
5. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
6. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
8. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
[TBL] [Abstract][Full Text] [Related]
9. Inhaled tiotropium for stable chronic obstructive pulmonary disease.
Barr RG; Bourbeau J; Camargo CA; Ram FS
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002876. PubMed ID: 15846642
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
12. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA; Shah M; D'Souza AO; Crater GD
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[TBL] [Abstract][Full Text] [Related]
13. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium as part of inhaled polytherapy: adherence and associated health-care utilization.
Simon-Tuval T; Maimon N
Respirology; 2015 Feb; 20(2):304-11. PubMed ID: 25511022
[TBL] [Abstract][Full Text] [Related]
16. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
17. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
18. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.
Salpeter SR
Drugs; 2009 Oct; 69(15):2025-33. PubMed ID: 19791824
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
[TBL] [Abstract][Full Text] [Related]
20. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]